Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Investigational New Drugs
|
July 6, 2026
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
Daruka Mahadevan, Jay Parekh, Joseph T Beck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2017
Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop
Kevin S Hughes, Edward P Ambinder, Gregory P Hess, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
Radj Gervais, John D Hainsworth, Normand Blais, et al.
ALTEX
|
November 12, 2018
Characterizing sources of variability in zebrafish embryo screening protocols
Jon T Hamm, Patricia Ceger, David Allen, et al.
Cancer
|
April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study
Jeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Clinical Breast Cancer
|
July 25, 2008
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
John T Hamm, John W Wilson, Priya Rastogi, et al.
Toxics
|
January 26, 2024
Interlaboratory Study on Zebrafish in Toxicology: Systematic Evaluation of the Application of Zebrafish in Toxicology's (SEAZIT's) Evaluation of Developmental Toxicity
Jon T Hamm, Jui-Hua Hsieh, Georgia K Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors
Gayle S Jameson, John T Hamm, Glen J Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2022
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Christina I Tsien, Stephanie L Pugh, Adam P Dicker, et al.
Breast Cancer Research and Treatment
|
March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Investigational New Drugs
|
July 6, 2026
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
Daruka Mahadevan, Jay Parekh, Joseph T Beck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2017
Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop
Kevin S Hughes, Edward P Ambinder, Gregory P Hess, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
Radj Gervais, John D Hainsworth, Normand Blais, et al.
ALTEX
|
November 12, 2018
Characterizing sources of variability in zebrafish embryo screening protocols
Jon T Hamm, Patricia Ceger, David Allen, et al.
Cancer
|
April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study
Jeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Clinical Breast Cancer
|
July 25, 2008
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
John T Hamm, John W Wilson, Priya Rastogi, et al.
Toxics
|
January 26, 2024
Interlaboratory Study on Zebrafish in Toxicology: Systematic Evaluation of the Application of Zebrafish in Toxicology's (SEAZIT's) Evaluation of Developmental Toxicity
Jon T Hamm, Jui-Hua Hsieh, Georgia K Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors
Gayle S Jameson, John T Hamm, Glen J Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2022
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Christina I Tsien, Stephanie L Pugh, Adam P Dicker, et al.
Breast Cancer Research and Treatment
|
March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Page
of 5